J
Jean-François Tanti
Researcher at French Institute of Health and Medical Research
Publications - 115
Citations - 16058
Jean-François Tanti is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Insulin receptor & Insulin. The author has an hindex of 47, co-authored 112 publications receiving 14354 citations. Previous affiliations of Jean-François Tanti include Centre national de la recherche scientifique & University of Nice Sophia Antipolis.
Papers
More filters
Journal ArticleDOI
Metabolic endotoxemia initiates obesity and insulin resistance
Patrice D. Cani,Jacques Amar,Miguel A. Iglesias,Marjorie Poggi,Claude Knauf,Delphine Bastelica,Audrey M. Neyrinck,Francesca Fava,Kieran Tuohy,Chantal Chabo,Aurélie Waget,Evelyne Delmée,Béatrice Cousin,Thierry Sulpice,Bernard Chamontin,Jean Ferrières,Jean-François Tanti,Glenn R. Gibson,Louis Casteilla,Nathalie M. Delzenne,Marie-Christine Alessi,Rémy Burcelin +21 more
TL;DR: It is concluded that the LPS/CD14 system sets the tone of insulin sensitivity and the onset of diabetes and obesity and lowering plasma LPS concentration could be a potent strategy for the control of metabolic diseases.
Journal ArticleDOI
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
TL;DR: This review will provide insight on the current understanding of the regulation of insulin signaling in both physiological and pathological conditions through modulations that occur with regards to the functions of the insulin receptor substrate 1 (IRS1).
Journal ArticleDOI
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra,Kathiane Laurent,Kathiane Laurent,Agnès Loubat,Agnès Loubat,Sophie Giorgetti-Peraldi,Sophie Giorgetti-Peraldi,Pascal Colosetti,Pascal Colosetti,Patrick Auberger,Patrick Auberger,Jean-François Tanti,Jean-François Tanti,Y. Le Marchand-Brustel,Y. Le Marchand-Brustel,Frédéric Bost,Frédéric Bost +16 more
TL;DR: Oral and intraperitoneal treatment with metformin led to a 50 and 35% reduction of tumor growth, respectively, in mice bearing xenografts of LNCaP, providing evidence for a mechanism that may contribute to the antineoplastic effects of met formin suggested by recent epidemiological studies.
Journal ArticleDOI
Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression.
TL;DR: Results demonstrate that IL-1beta reduces IRS-1 expression at a transcriptional level through a mechanism that is ERK dependent and at a posttranscriptional level independently of ERK activation, and could thus participate in concert with other cytokines, in the development of insulin resistance in adipocytes.
Journal ArticleDOI
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
Isaam Ben Sahra,Claire Regazzetti,Guillaume Robert,Kathiane Laurent,Yannick Le Marchand-Brustel,Patrick Auberger,Jean-François Tanti,Sophie Giorgetti-Peraldi,Frédéric Bost +8 more
TL;DR: RedD1 (also known as DDIT4 and RTP801), a negative regulator of mTOR, is identified as a new molecular target of metformin and inhibition of REDD1 reverses meetformin-induced cell-cycle arrest and significantly protects from the deleterious effects of met formin on cell transformation.